MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Ali KESHAVARZ-SHOKRI, Alexander Russell ABELA, Pramod Virupax JOSHI, Paul Jhon KRENITSKY, Haripada KHATUYA, Raymond Stanley GROSS, Timothy ALCACIO, Jason MCCARTNEY, Robert M. HUGHES, Jinglan ZHOU, Jeremy J. CLEMENS, Fabrice Jean Denis PIERRE, David Andrew SIESEL, Muna SHRESTHA, Mark Thomas MILLER, Peter Diedierik Jan GROOTENHUIS, Ping KANG, Clara Kuang-ju HSIA, Minson BAEK, Andreas P. TERMIN, Thomas CLEVELAND, Fredrick F. VAN GOOR, Sara Sabina HADIDA RUAH, Corey ANDERSON, Johnny UY, Lori Ann FERRIS, Anton GULEVICH, Tomothy John YOUNG, Yi SHI, Paul Timothy ANGELL, Prasuna PARASELLI, Kathy STAVROPOULOS
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof. Se describen compuestos de Fórmula (I): (ver fórmulas) sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.